In a sharp contrast to c-myc, the expression of N-MYC is largely restricted to embryonic tissues and neuroendocrine tumors (Boon et al., 2001) . It has been established that N-MYC gene amplification is strongly associated with poor clinical outcome of aggressive human neuroblastoma (Kohl et al., 1983; Schwab et al., 1983; Seeger et al., 1985) . Indeed, enforced expression of N-MYC in neuroblastoma cell lines resulted in an accelerated proliferation (Bernards et al., 1986; Lutz et al., 1996) , whereas treatment of neuroblastoma cells with antisense oligonucleotides specific to N-MYC decreased their proliferation (Negroni et al., 1991) . Consistent with these observations, transgenic mice overexpressing N-MYC in neural crest-derived tissues displayed frequent development of neuroblastomas (Weiss et al., 1997) , suggesting that deregulated expression of N-MYC is causative in genesis and development of neuroblastoma in vivo. However, it is still unclear how N-MYC contributes to the formation of neoplastic phenotypes of neuroblastoma.
N-MYC is a nuclear transcription factor containing NH 2 -terminal transactivation domain and COOH-terminal helix-loop-helix/leucine-zipper domain as well as the basic region (Kouzarides and Ziff, 1988; Landschulz et al., 1988; Murre et al., 1989) . N-MYC forms a heterodimeric complex with Max through their helixloop-helix/leucine-zipper domains and binds to consensus site known as E-box (CACGTG) (Alex et al., 1992; Blackwood et al., 1992; Torres et al., 1992) . Identification of its direct transcriptional target gene(s) might provide a novel insight into understanding the functional contribution of N-MYC in malignant phenotypes of aggressive neuroblastoma. Extensive efforts demonstrated that prothymosin-a, ornithine decarboxylase teromerase reverse transcriptase, Id2 and genes involved in ribosome biogenesis are transcriptional targets of N-MYC (Lutz et al., 1996; Wang et al., 1998; Lasorella et al., 2000; Boon et al., 2001) . Recently, Slack et al. (2005) described that MDM2 that acts as an E3 ubiquitin protein ligase for tumor suppressor, p53, is a putative transcriptional target of N-MYC. According to their results, N-MYC directly binds to a consensus E-box within human MDM2 promoter region and N-MYC has an ability to transactivate MDM2 promoter. Furthermore, the endogenous MDM2 increased in N-MYCinducible neuroblastoma cells. These observations suggest that MDM2 is important in N-MYC-driven neuroblastoma development.
Mammalian neuronal leucine-rich repeat protein family (NLRR) is a type I transmembrane protein with extracellular leucine-rich repeats, which is composed of NLRR1-5 (Taguchi et al., 1996; Taniguchi et al., 1996; Hamano et al., 2004; Bando et al., 2005) . NLRR proteins have been proposed to function as cell adhesion or signaling molecules (Fukamachi et al., 2002) . We have previously reported that expression levels of NLRR1 are significantly higher in unfavorable neuroblastoma than those in favorable one and higher expression levels of NLRR1 closely correlate with poor clinical outcome of patients with neuroblastoma (Hamano et al., 2004) . In contrast, NLRR3 and NLRR5 were expressed at higher levels in favorable neuroblastoma as compared with unfavorable one. For NLRR2, no significant differences were observed in its expression levels between favorable and unfavorable neuroblastomas (Hamano et al., 2004) . In the present study, we have found that NLRR1 is a direct transcriptional target of N-MYC and its gene product is important in the regulation of neuroblastoma cell proliferation.
To examine a possible correlation between expression levels of N-MYC and NLRR1 in neuroblastoma cells, total RNA was prepared from the indicated cell lines and subjected to reverse transcription (RT)-PCR. As shown in Figure 1a , all neuroblastoma cell lines At the indicated time periods after the addition of Tc (100 ng/ml), total RNA and cell lysates were prepared and subjected to RT-PCR (d) and immunoblotting (e), respectively. (f) Expression of NLRR1 in primary neuroblastomas. Total RNA was prepared from eight favorable neuroblastomas (cases 1-8) and eight unfavorable ones (cases 9-16) and subjected to RT-PCR to examine expression levels of N-MYC (top) and NLRR1 (middle). GAPDH was used as an internal control (bottom). (g) Immunohistochemical analysis. Primary neuroblastomas tissues with N-MYC amplification were immunostained with anti-NLRR1 (left panels) or with anti-N-MYC antibody (right panels). The BenchMark XT immunostainer (Ventana Medical Systems, Tucson, AZ, USA) and 3,3 0 diaminobenzidine detection kit (Ventana Medical Systems) were used to visualize NLRR1 and N-MYC. All patients agreed to participate and provided written informed consent and our present study was approved by institutional ethical review committee.
with N-MYC amplification that we examined expressed NLRR1 mRNA, whereas we did not detect NLRR1 mRNA in OAN, SH-SY5Y and SK-N-AS cells bearing a single copy of N-MYC under our experimental conditions. To confirm a possible relationship between N-MYC and NLRR1, we employed N-MYC-inducible neuroblastoma cells (Tet21N) derived from parental neuroblastoma cell line SHEP (Lutz et al., 1996) . According to their results, Tet21N cells constitutively expressed N-MYC in the absence of tetracycline (Tc), whereas the addition of Tc to the culture decreased N-MYC expression levels. For this purpose, we have generated polyclonal antibody against NLRR1 that recognizes the region including amino-acid residues between positions 693 and 712. At the indicated time points after Tc depletion, total RNA and cell lysates were prepared and subjected to RT-PCR and immunoblotting, respectively. As shown in Figure 1b , Tc deprivation led to an induction of N-MYC in association with a significant increase in expression levels of NLRR1. Similar results were also obtained in immunoblotting analysis ( Figure 1c ). In contrast to the withdrawal of Tc, the addition of Tc to the culture significantly reduced expression levels of N-MYC and the concomitant decrease in expression levels of NLRR1 was detectable at mRNA and protein levels (Figures 1d and e), suggesting that NLRR1 might be a direct transcriptional target of N-MYC.
Consistent with these results, NLRR1 expression was undetectable in favorable primary neuroblastomas carrying a single copy of N-MYC, whereas unfavorable primary neuroblastomas bearing N-MYC amplification expressed substantial amounts of NLRR1 (Figure 1f ). Immunohistochemical analyses also revealed that NLRR1 is coexpressed with N-MYC in primary neuroblastomas bearing N-MYC amplification ( Figure 1g ). On the other hand, NLRR1 was undetectable in primary neuroblastomas carrying a single copy of N-MYC (data not shown). In addition, Spearman's rank correlation coefficient between NLRR1 and MYCN mRNA expression in 136 primary neuroblastomas was 0.42 (Po0.0001) as shown in the scatter plot of Supplementary Figure S1 , suggesting that NLRR1 and MYCN expression in primary tumors is also positively correlated.
To address whether N-MYC could enhance the transcription of NLRR1, HeLa cells were transfected with or without the increasing amounts of the expression plasmid encoding N-MYC. As clearly shown in Supplementary Figure S2 , N-MYC had an ability to transactivate the endogenous NLRR1 in a dose-dependent manner. In contrast, N-MYC had undetectable effects on expression levels of the endogenous NLRR2 (data not shown). Intriguingly, c-myc was also capable to transactivate the endogenous NLRR1 (Supplementary Figure S2 ). Expression levels of cyclin E were examined as a positive control. As it has been well established that N-MYC recognizes and binds to socalled E-box (5 0 -CACGTG-3 0 ), we sought to find out the putative E-box sequence(s) within 5 0 -upstream region as well as intron 1 of NLRR1 gene. Finally, we found out three (E-1, E-2 and E-3) and two candidate E-boxes (E-4 and E-5) within 5 0 -upstream region and intron 1 of NLRR1 gene, respectively (Figure 2a ). To investigate whether these canonical E-boxes could respond to N-MYC, we subcloned genomic fragments containing each of these putative E-boxes into luciferase reporter plasmid to give pluc-E1, pluc-E2, pluc-E3, pluc-E4 and pluc-E5. SK-N-AS cells carrying a single copy of N-MYC were co-transfected with the constant amount of the expression plasmid for N-MYC and Renilla luciferase reporter plasmid together with the indicated luciferase reporter plasmids. At 48 h after transfection, cells were lysed and their luciferase activities were measured. As shown in Figure 2b , E-1 and E-4 boxes showed the relatively higher luciferase activities than those of the remaining putative E-box-containing fragments. Similar results were also obtained in mouse neuroblastoma Neuro2a cells (data not shown). Thus, we focused our attention on E-1 and E-4 boxes. To verify the functional significance of E-1 and/or E4 box, we have disrupted E-1 or E-4 box to give pluc-E1D or pluc-E4D luciferase reporter construct. Luciferase reporter assays demonstrated that pluc-E1D and pluc-E4D do not respond to exogenously expressed N-MYC (Figure 2c ). These results indicate that E-1 and E-4 boxes are the functional elements involved in N-MYCdependent transcriptional activation of NLRR1.
To ask whether N-MYC could be recruited onto E-1 and/or E-4 box in cells, we performed chromatin immunoprecipitation (ChIP) assays. Cross-linked chromatin prepared from the indicated cells was immunoprecipitated with normal mouse serum or with monoclonal anti-N-MYC antibody. Under our experimental conditions, an average length of sonicated genomic DNA fragments was 200-800 nucleotides in length (data not shown). The genomic DNA was purified from immunoprecipitates and amplified by PCR. As shown in Figure 2d , the estimated sizes of PCR products containing E-1 or E-4 box were detectable in IMR-32, SAN and CHP134 cells with N-MYC amplification, whereas our ChIP assays did not detect the estimated PCR products in SK-N-AS and SH-SY5Y cells bearing a single copy of N-MYC. In addition, we could not detect the efficient recruitment of N-MYC onto E-3 box that did not respond to exogenously expressed N-MYC. Consistent with these results, the anti-N-MYC immunoprecipitates prepared from Tet21N cells maintained in the absence of Tc contained the genomic fragments encompassing E-1 and E-4 boxes. In a sharp contrast, genomic fragment including E-3 box was not detectable in the anti-N-MYC immunoprecipitates prepared from Tet21N cells cultured in the absence of Tc. These observations suggest that N-MYC is recruited onto E-1 and E-4 boxes of NLRR1 gene in cells.
We next examined a possible effect of NLRR1 on cell growth of neuroblastoma cells. SK-N-BE cells were transfected with the empty plasmid or with the expression plasmid for Myc-tagged NLRR1 (NLRR1-Myc). At 48 h after transfection, cells were transferred into fresh medium containing G418 for 2 weeks.
Drug-resistant cells were collected and their growth was examined. As shown in Figure 3a , exogenous NLRR1-Myc was expressed in drug-resistant cells transfected with NLRR1-Myc expression plasmid. Of note, NLRR1-Myc transfectants displayed an accelerated proliferation as compared with the control transfectants (Po0.01; Figure 3b) . To investigate the possible role of the endogenous NLRR1, we have designed smallinterfering RNA (siRNA) against NLRR1. As shown in Figure 3c , siRNA-targeting NLRR1 significantly downregulated the expression levels of the endogenous NLRR1 in SK-N-BE cells. As expected, siRNAmediated knockdown of the endogenous NLRR1 significantly reduced the rate of cell growth as compared , Renilla luciferase reporter plasmid (pRL-TK, 10 ng) and luciferase reporter plasmid containing E-1, E-2, E-3, E-4 or E-5 box (100 ng). Total amount of plasmid DNA per transfection was kept constant (510 ng) with pcDNA3. At 48 h after transfection, cells were lysed and their luciferase activities were measured by Dual-Luciferase reporter system (Promega, Madison, WI, USA). The firefly luminescence signal was normalized based on the Renilla luminescence signal. The results were obtained at least three independent experiments. (c) E-1 and E-4 boxes are required for N-MYC-dependent transactivation of NLRR1 promoter. SK-N-AS cells were cotransfected with the constant amount of the expression plasmid for N-MYC (100 ng), pRL-TK (10 ng) and luciferase reporter plasmid lacking E-1 (pluc-E1D) or E-4 box (pluc-E4D). At 48 h after transfection, cells were lysed and their luciferase activities were measured as in (b). (d) N-MYC is efficiently recruited onto E-1 and E-4 boxes. Chromatin immunoprecipitation (ChIP) assays were carried out using chromatin immunoprecipitation assay kit provided from Upstate (Charlottesville, VA, USA). In brief, the indicated cells were cross-linked with formaldehyde and cross-linked chromatin was sonicated followed by immunoprecipitation with normal mouse serum (NMS) or with monoclonal anti-N-MYC antibody. Genomic DNAs were purified from the immunoprecipitates and subjected to PCR to amplify the genomic region containing E-1, E-3 and E-4 boxes. The oligonucleotide primer sequences used in this study are as follows: E-1, 5 0 -AAGTTGGATTTGATGACTGATACG-3 0 (sense) and 5 0 -AGGCAAGAGACCATGTGCAGGAG-3 0 (antisense); E-3, 5 0 -ATGAATCGAACAGTGGAGAGAC-3 0 (sense) and 5 0 -AATGCTTAGGACAGTGCTTAG-3 0 (antisense); E-4, 5 0 -TGTCTA ACATTAGCTGCGTGACC-3 0 (sense) and 5 0 -AATGCTGTTCCGTGAATAGGTTC-3 0 (antisense).
with the control cells (Po0.01; Figure 3d ), indicating that NLRR1 has an ability to promote cell growth in neuroblastoma. As described previously (Hamano et al., 2004) , NLRR1 was expressed at significantly higher levels in unfavorable neuroblastoma than favorable one, indicating that NLRR1 might have an anti-apoptotic activity. To address this issue, SK-N-BE and SH-SY5Y cells were transfected with the empty plasmid or with the expression plasmid for NLRR1-Myc. At 48 h after transfection, cells were exposed to G418 for 2 weeks. Drug-resistant cells were collected and cultured in the presence or absence of fetal bovine serum (FBS). At 24 h after FBS starvation, floating and attached cells were harvested, stained with propidium iodide and measured number of cells with sub-G 0 /G 1 DNA content by fluorescence-activated cell sorting (FACS) analysis. As shown in Figure 3e , FBS deprivation increased number of parental and control SK-N-BE cells with sub-G 0 /G 1 DNA content as compared with those cultured in the presence of FBS, whereas enforced expression of NLRR1-Myc significantly decreased number of cells with sub-G 0 /G 1 DNA content relative to parental and control cells under FBS deprivation. Similar results were also obtained in SH-SY5Y cells (Figure 3e ).
In support with these results, cleaved caspase-3 was detectable in control SK-N-AS transfectants maintained in the absence of FBS, whereas we did not detect cleaved caspase-3 in NLRR1-Myc transfectants under FBS deprivation (Figure 4a ). Cleaved caspase-3 was also detected in parental cells in the absence of FBS (Figure 4b ). In addition, cleaved poly-(ADP-ribose) . SK-N-BE cells were transfected with control siRNA or with siRNA against NLRR1 (20 nM, Takara, Ohtsu, Japan) using Lipofectamine RNAiMAX (Invitrogen). At 48 h after transfection, cell lysates were prepared and subjected to immunoblotting with anti-NLRR1 antibody. (d) Growth curves. SK-N-BE cells were transfected as in (c). At 24 h after transfection, attached cells were collected and seeded at a density of 1 Â 10 5 cells per cell culture plates. At the indicated time points after seeding the cells, number of viable cells were measured and presented by graphs. Solid triangles, circles and squares indicate parental cells, control transfectants and NLRR1-knocked down cells, respectively. *Po0.01. (e) NLRR1 has an anti-apoptotic potential in response to fetal bovine serum (FBS) starvation. SK-N-BE and SH-SY5Y cells were transfected with the empty plasmid or with the expression plasmid encoding NLRR1-Myc. At 48 h after transfection, cells were transferred into fresh medium containing G418 (600 mg/ml). After 2 weeks of selection, drug-resistant cells were harvested and cultured in the presence or absence of FBS. At 24 h after treatment, floating and attached cells were collected, stained with propidium iodide (PI) and their cell-cycle distributions were analysed by fluorescenceactivated cell sorting (FACS, Becton Dickinson, Mountain View, CA, USA). Results obtained by FACS analysis were presented by graphs. Open, gray and solid boxes indicate parental cells, control transfectants and NLRR1-Myc-expressing transfectants, respectively. *Po0.01, **Po0.01. polymerase (PARP) that is one of caspase-3 substrates (Truscott et al., 2007) , started to be observed in control transfectants 12 h after FBS starvation (Figure 4c ). On the other hand, the kinetics for cleavage of PARP was delayed in NLRR1-Myc transfectants. Under our experimental conditions, control SK-N-AS transfectants underwent apoptosis in response to FBS deprivation, whereas enforced expression of NLRR1-Myc in SK-N-AS cells inhibited the FBS deprivation-induced apoptosis (data not shown). These findings suggest that NLRR1 confers resistance of neuroblastoma cells to FBS starvation-induced apoptosis.
To further confirm this notion, Tet21N cells were maintained in the absence of Tc and then transfected with control siRNA or with siRNA against NLRR1. At 48 h after transfection, cells were cultured in the absence of FBS for 24 h and then their cell-cycle distributions were analysed by FACS. As shown in Figures 4d and e , siRNAmediated knockdown of the endogenous NLRR1 resulted in a significant increase in number of cells with sub-G 0 /G 1 DNA content in response to FBS deprivation as compared with parental cells and control transfectants. Collectively, our present results strongly suggest that NLRR1 is a novel transcriptional target of N-MYC and has a growthpromoting as well as anti-apoptotic potential.
Small-interfering RNA-mediated knockdown of the endogenous NLRR1 in SK-N-BE cells bearing N-MYC amplification resulted in a significant decrease in the rate of cell growth. Furthermore, enforced expression of NLRR1-Myc conferred resistance of SK-N-BE and SH-SY5Y cells to FBS deprivation-mediated apoptosis. In contrast, siRNA-mediated knockdown of the endogenous NLRR1 led to an increase in number of cells with sub-G 0 /G 1 DNA content in response to FBS deprivation. In addition, NLRR1-Myc blocked the activation of caspase-3 in SK-N-AS cells exposed to FBS depletion and thereby inhibiting the proteolytic cleavage of PARP. Thus, it is conceivable that NLRR1 inhibits the mitochondria-dependent intrinsic apoptotic pathway of caspase activation (Degterev et al., 2003) . As reported previously (Hamano et al., 2004) , expression levels of NLRR1 in unfavorable neuroblastoma were significantly higher than those of favorable one and closely correlated with poor clinical outcome. As aggressive neuroblastoma displays unfavorable clinical outcome despite intensive chemotherapy (Brodeur and Nakagawara, 1992) , it is likely that N-MYC-mediated induction of NLRR1 is involved in the regulation of chemoresistant phenotypes of certain neuroblastomas. However, precise molecular mechanisms behind NLRR1-mediated growth promotion and anti-apoptotic effect in response to FBS starvation remain unclear. Further studies should be necessary to address this issue. According to our present results, N-MYC-dependent transcriptional induction of NLRR1 was observed in neuroblastoma cell lines. Furthermore, expression levels of NLRR1 significantly correlated with those of N-MYC in primary neuroblastomas. Intriguingly, the enforced expression of N-MYC in HeLa cells also induced the expression of NLRR1, indicating that N-MYCmediated transcriptional activation of NLRR1 is not restricted to neuroblastoma cells. As described previously (Blackwood and Eisenman, 1991; Torres et al., 1992) , c-myc/Max heterodimeric complex also recognizes and binds to E-box. Like N-MYC, c-myc had an ability to induce the expression of NLRR1. Of note, our luciferase reporter assays indicated that E-1 and E-4 boxes are required for N-MYC-dependent activation of NLRR1 promoter, whereas E-3 box does not respond to N-MYC. Similar results were also obtained in cells transfected with the expression plasmid for c-myc (data not shown). As described previously (Hamano et al., 2004) , NLRR1 was expressed ubiquitously in human tissues. Among them, higher levels of NLRR1 expression were observed in nerve tissues. Considering that N-MYC expression is largely restricted to embryonic tissues as well as neuroendocrine tumors, whereas c-myc is expressed in a wide variety of tissues as well as tumors (Boon et al., 2001) , N-MYC and c-myc might act as transcription factors for NLRR1 in a cell-typedependent manner under physiological conditions.
In the present study, we have found that NLRR1 is one of direct transcriptional targets of oncogenic N-MYC and is important in the regulation of cell proliferation and the protection of cells from FBS deprivation-induced apoptosis in neuroblastoma cells. In support with this notion, there exists a positive correlation between expression levels of N-MYC and NLRR1 in primary neuroblastomas. To our knowledge, NLRR1 is a first membrane protein whose expression levels are directly regulated by N-MYC. Thus, our present findings might provide a novel insight into understanding molecular mechanisms behind genesis and development of aggressive neuroblastoma with N-MYC amplification.
